Cetrorelix

Indications

For inhibition of premature LH (luteinizing hormone) surges in women undergoing controlled ovarian stimulation.

Dosage

Ovarian stimulation therapy with gonadotropins (FSH-Follicel stimulating hormone, hMG-human menopausal gonadotropin) is stared on cycle Day 2 or 3. Cetrorelix acetate may be administered subcutaneously either once daily (0.25mg) or once (3mg) during the early- to mid-follicular phase.

Contra-Indications

Hypersensitivity to cetrorelix acetate, extrinsic peptide hormones or mannitol; known hypersensitivity to gonadotropin releasing hormone (GnRH); known or suspected pregnancy; lactation; severe renal impairment. Elderly aged 65 or over.

Special Precautions

Before starting treatment pregnancy must be excluded. Active allergic conditions or known history of allergic predisposition.

Side Effects

Ovarian hyperstimulation syndrome, nausea, headache, local site reactions (eg. redness, erythema, bruising, itching, swelling, and pruritus). Hypersensitivity reactions (rarely). Elevation of ALT, AST, GGT, alkaline phosphatase (1-2% patients).

Drug Interactions

No formal drug interaction studies have been performed.